Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic equivalence of DMB-3115 versus Stelara in moderate to severe chronic plaque psoriasis
2020-005108-21Phase 3Completed
- Sponsor
- Dong-A ST
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dmb-3115 in psoriasis (2 arms), sponsored by Dong-A ST. Primary endpoint: Percent change in PASI score from baseline to Week 8. Started Feb 2021; status: completed.
02
Drugs
dmb-3115
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2020-005108-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005108-21.